Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2020. szeptember 22., kedd 15:30 |
Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market |
|
Rheinbreitbach/Bonn, 22 September, 2020 (APA/OTS) - Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/Denmark, to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an agreement to acquire all shares in Jennewein Biotechnologie, the innovation and market leader in this high-growth market. Chr. Hansen plans to invest more than 200 million Euros until 2025 in new production assets so as to meet the increasing demand for HMOs. |
HMOs are complex carbohydrate structures found in human breast milk.
HMOs are used today as functional food ingredients primarily in
infant nutrition and medical nutrition. The functional health
benefits of HMOs such as prebiotic effects, reducing infection risk
as well as supporting cognitive development are also expected to be
of high interest in further food markets. Jennewein Biotechnologie
has been the first to commercially produce HMOs by fermentation and
commercialize these functional carbohydrates in key markets.
Jennewein Biotechnologie has build an unrivaled IP portfolio with
more than 200 patents granted, a global customer base, a
comprehensive product portfolio and strong product pipeline over the
past 15 years.
The founders and CEOs of Jennewein Biotechnologie, Dr. Stefan
Jennewein and Dr. Klaus Jennewein point out: "This partnership will
further strengthen the position of Jennewein Biotechnologie in this
highly attractive growth market. Chr. Hansen and Jennewein
Biotechnologie are a perfect fit with regards to culture, production
technology, as well as product portfolio."
"I am truly excited that we have reached an agreement to acquire
Jennewein. The fast-growing HMO market is a new area that we have
been following with strong interest for some years. In truth we are
making a long-term investment and commitment to HMOs, which I am
convinced will bring long-term value creation to our shareholders.
HMOs also fit perfectly with our purpose to "Grow a better world
naturally", as these are some of nature's most intricate nutritional
components" says Mauricio Graber, CEO of Chr. Hansen.
"With Chr. Hansen as the new owner, Jennewein Biotechnologie is
ideally positioned for future growth and expansion. As a partner to
Jennewein from the very beginning and long-time investor we are
proud to have been part in this success story" states Dr. Erik
Hoppe, CEO of Bioventure and Lead Investor of Jennewein
Biotechnologie.
Dr. Stefan Jennewein will take the role of Chief Science and
Technology Advisor and Dr. Klaus Jennewein will retire from the
company.
UBS acted as financial adviser and Hogan Lovells as legal adviser
to Jennewein Biotechnologie and Bioventure on this transaction.
About Jennewein Biotechnologie GmbH Jennewein Biotechnologie is a leading international industrial
biotechnology company with a range of products in the field of human
milk oligosaccharides (HMOs) and rare monosaccharides such as
L-Fucose and Sialic acid. The company manufactures an extensive
portfolio of innovative HMO products, such as 2' fucosyllactose,
3'-fucosyllactose, Lacto-N-neotetraose, and lacto-N-tetraose. These
rare sugars are used in the food industry (particularly infant milk
formulas), the pharmaceutical industry, and the cosmetic industry.
Jennewein Biotechnologie GmbH was founded in 2005 in Bonn and is
headquartered in Rheinbreitbach (Rheinland-Pfalz).
About Chr. Hansen Chr. Hansen is a leading, global bioscience company that develops
natural ingredient solutions for the food, nutritional,
pharmaceutical and agricultural industries. We develop and produce
cultures, enzymes, probiotics and natural colors for a rich variety
of foods, confectionery, beverages, dietary supplements and even
animal feed and plant protection. Our product innovation is based on
around 40,000 microbial strains - we like to refer to them as 'good
bacteria'. Our solutions enable food manufacturers to produce more
with less - while also reducing the use of chemicals and other
synthetic additives - which make our products highly relevant in
today's world. Sustainability is an integral part of Chr. Hansen's
vision to improve food and health. In 2019 Chr. Hansen was ranked as
the world's most sustainable company by Corporate Knights thanks to
our strong sustainability efforts and our many collaborative
partnerships with our customers. We have been delivering value to
our partners - and, ultimately, end consumers worldwide - for over
140 years. We are proud that more than one billion people consume
products containing our natural ingredients every day.
For further information please contact:
Bettina Gutiérrez, Press and Public Relations Jennewein
Biotechnologie GmbH, Tel:+ 49 2224 98810797 Martin Riise, Head of Investor Relations Chr. Hansen Holding S/A,
Tel: +45 5339 2250 Annika Stern, Investor Relations Officer Chr. Hansen Holding S/A,
Tel: +45 2399 2382 Camilla Lercke, Head of Media Relations Chr. Hansen Holding S/A,
Tel: +45 5339 2384
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|